Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Tumor-Infiltrating Myeloid Cells; Mechanisms, Functional Significance, and Targeting in Cancer Therapy Publisher



Toghraie FS1 ; Bayat M2 ; Hosseini MS4 ; Ramezani A2, 3
Authors
Show Affiliations
Authors Affiliations
  1. 1. Institute of Biotechnology, Faculty of the Environment and Natural Sciences, Brandenburg University of Technology, Cottbus, Germany
  2. 2. Shiraz Institute for Cancer Research, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
  3. 3. Department of Medical Biotechnology, School of Advanced Medical Sciences and Technologies, Shiraz University of Medical Sciences, Shiraz, Iran
  4. 4. Regenerative Medicine Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

Source: Cellular Oncology Published:2025


Abstract

Tumor-infiltrating myeloid cells (TIMs), which encompass tumor-associated macrophages (TAMs), tumor-associated neutrophils (TANs), myeloid-derived suppressor cells (MDSCs), and tumor-associated dendritic cells (TADCs), are of great importance in tumor microenvironment (TME) and are integral to both pro- and anti-tumor immunity. Nevertheless, the phenotypic heterogeneity and functional plasticity of TIMs have posed challenges in fully understanding their complexity roles within the TME. Emerging evidence suggested that the presence of TIMs is frequently linked to prevention of cancer treatment and improvement of patient outcomes and survival. Given their pivotal function in the TME, TIMs have recently been recognized as critical targets for therapeutic approaches aimed at augmenting immunostimulatory myeloid cell populations while depleting or modifying those that are immunosuppressive. This review will explore the important properties of TIMs related to immunity, angiogenesis, and metastasis. We will also document the latest therapeutic strategies targeting TIMs in preclinical and clinical settings. Our objective is to illustrate the potential of TIMs as immunological targets that may improve the outcomes of existing cancer treatments. © The Author(s) 2025.
Related Docs
View other Related Docs
1. Genetically Engineered Mesenchymal Stem Cells: Targeted Delivery of Immunomodulatory Agents for Tumor Eradication, Cancer Gene Therapy (2020)
2. Investigating the Dynamic Interplay Between Cellular Immunity and Tumor Cells in the Fight Against Cancer: An Updated Comprehensive Review, Iranian Journal of Blood and Cancer (2024)
3. Prophylactic Dna Vaccine Targeting Foxp3+ Regulatory T Cells Depletes Myeloid-Derived Suppressor Cells and Improves Anti-Melanoma Immune Responses in a Murine Model, Cancer Immunology, Immunotherapy (2018)
4. The Role of Distinct Subsets of Macrophages in the Pathogenesis of Ms and the Impact of Different Therapeutic Agents on These Populations, Frontiers in Immunology (2021)
5. Combination Therapy With Nivolumab (Anti-Pd-1 Monoclonal Antibody): A New Era in Tumor Immunotherapy, International Immunopharmacology (2022)
6. Cancer Vaccines As a Targeted Immunotherapy Approach for Breast Cancer: An Update of Clinical Evidence, Expert Review of Vaccines (2022)
7. Immune-Dysregulation Harnessing in Myeloid Neoplasms, Cancer Medicine (2024)
8. Preparation and Characterization of a Novel Nanobody Against T-Cell Immunoglobulin and Mucin-3 (Tim-3), Iranian Journal of Basic Medical Sciences (2016)
Experts (# of related papers)
View all Related Experts
Mazdak Ganjalikhani Hakemi (12)
Hossein Khanahmad (5)
Other Related Docs
9. Myeloid-Derived Suppressor Cells Elimination by 5-Fluorouracil Increased Dendritic Cell-Based Vaccine Function and Improved Immunity in Tumor Mice, Iranian Journal of Allergy, Asthma and Immunology (2018)
10. The Correlation Between Flt3-Itd Mutation in Dendritic Cells With Tim-3 Expression in Acute Myeloid Leukemia, Blood Science (2021)
11. Study of T-Cell Immunoglobulin and Mucin Domain-3 Expression Profile in Peripheral Blood and Bone Marrow of Human Acute Lymphoblastic Leukemia Patients, Journal of Research in Medical Sciences (2020)
12. Evaluation of Silencing Effect of Mir-133A-5P Mimic on Tim-3 Expression in Aml (Hl-60) Cell Line, Indian Journal of Clinical Biochemistry (2020)
13. Oncolytic Newcastle Disease Virus Delivered by Mesenchymal Stem Cells-Engineered System Enhances the Therapeutic Effects Altering Tumor Microenvironment, Virology Journal (2020)
14. The Role of Tim-3 in Hepatocellular Carcinoma: A Promising Target for Immunotherapy?, Frontiers in Oncology (2020)
15. Immune Evader Cancer Stem Cells Direct the Perspective Approaches to Cancer Immunotherapy, Stem Cell Research and Therapy (2022)
16. Tim-3/Gal-9 Interaction Affects Glucose and Lipid Metabolism in Acute Myeloid Leukemia Cell Lines, Frontiers in Immunology (2023)
17. Evaluation of the Effect of Tim-3 Suppression by Mir-498 and Its Effect on Apoptosis and Proliferation Rate of Hl-60 Cell Line, Pathology Research and Practice (2018)
18. Tim-3 in Leukemia; Immune Response and Beyond, Frontiers in Oncology (2021)
19. The Nexus of Natural Killer Cells and Melanoma Tumor Microenvironment: Crosstalk, Chemotherapeutic Potential, and Innovative Nk Cell-Based Therapeutic Strategies, Cancer Cell International (2023)
20. Don't Eat Me/Eat Me Signals As a Novel Strategy in Cancer Immunotherapy, Heliyon (2023)
21. Tumor-Associated Macrophages and Epithelial–Mesenchymal Transition in Cancer: Nanotechnology Comes Into View, Journal of Cellular Physiology (2018)
22. The Roles of Tumor-Derived Exosomes in Altered Differentiation, Maturation and Function of Dendritic Cells, Molecular Cancer (2021)
23. The Role of Bone Marrow Microenvironment (Bmm) Cells in Acute Myeloid Leukemia (Aml) Progression: Immune Checkpoints, Metabolic Checkpoints, and Signaling Pathways, Cell Communication and Signaling (2023)
24. The Mir-125A-3P Inhibits Tim-3 Expression in Aml Cell Line Hl-60 in Vitro, Indian Journal of Hematology and Blood Transfusion (2017)
25. Intersecting Pathways: The Role of Hybrid E/M Cells and Circulating Tumor Cells in Cancer Metastasis and Drug Resistance, Drug Resistance Updates (2024)
26. Evaluating T-Cell Immunoglobulin Mucin-3 (Tim-3) Receptor in the Growth Inhibition of Acute Lymphoblastic Leukemia (All) Cell Lines, Journal of Isfahan Medical School (2015)
27. The Pro-Tumorigenic Responses in Metastatic Niches: An Immunological Perspective, Clinical and Translational Oncology (2023)
28. Micro-Rnas As Critical Regulators of Matrix Metalloproteinases in Cancer, Journal of Cellular Biochemistry (2018)
29. Application of Mesenchymal Stem Cells in Melanoma: A Potential Therapeutic Strategy for Delivery of Targeted Agents, Current Medicinal Chemistry (2016)
30. Immune Checkpoint Inhibitors As Mediators for Immunosuppression by Cancer-Associated Fibroblasts: A Comprehensive Review, Frontiers in Immunology (2022)
31. Mesenchymal Stem Cell-Released Oncolytic Virus: An Innovative Strategy for Cancer Treatment, Cell Communication and Signaling (2023)
32. Tim3 and Pd-1 As a Therapeutic and Prognostic Targets in Colorectal Cancer: Relationship With Sidedness, Clinicopathological Parameters, and Survival, Frontiers in Oncology (2023)
33. Immunologic Tumor Microenvironment Modulators for Turning Cold Tumors Hot, Cancer Communications (2024)
34. Comparison of Four Methods of Colon Cancer Cell Lysates Preparation for Ex Vivo Maturation of Dendritic Cells, Research in Pharmaceutical Sciences (2022)
35. Negative Regulation of Tim-3 Expression in Aml Cell Line (Hl-60) Using Mir-330-5P, British Journal of Biomedical Science (2016)
36. Toll‑Like Receptor 4, 2, and Interleukin 1 Receptor Associated Kinase4: Possible Diagnostic Biomarkers in Myelodysplastic Syndrome Patients, Advanced Biomedical Research (2024)
37. Clinical Combinatorial Treatments Based on Cancer Vaccines: Combination With Checkpoint Inhibitors and Beyond, Current Drug Targets (2022)
38. Silencing of Tim-3 Expression by Mir-326 Affects Apoptosis and Proliferation of Human Hl-60 Leukemia Cell Line, UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi (2018)